Login to Your Account



Financings Roundup


Thursday, December 16, 2010
Genta Inc., of Berkeley Heights, N.J., received $5 million from a control account related to its $25 million private placement of convertible notes issued in March 2010. Proceeds will be used to determine survival data from Genta's Phase III trial of Genasense (oblimersen sodium) for melanoma and to accelerate development of other pipeline products.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription